Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
Pharma News, 2025
GTCR
GTCR to acquire generic drug maker Zentiva
Adjunctive Use Approved CBD
Study: Adjunctive Use of FDA-Approved CBD Formulation Reduces Seizures in Pediatric Patients With Rett Syndrome
Sanofi’s Tzield
Sanofi’s Tzield gains approval in China for T1D management
Capricor
Capricor refutes FDA’s DMD deramiocel rejection in public statement
Medison and Ipsen’s Bylvay
Health Canada approves Medison and Ipsen’s Bylvay to treat ALGS
ART12.11
New Preclinical Data on ART12.11 for the Treatment of Mood and Anxiety Disorders
FDA Continues Focus
FDA Continues Focus on Rare Disease Drug Development, Announces Evidence Principles
Tolerance Bio and ZipCode Bio
Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics
Novartis snaps
Novartis snaps up promising ASCVD asset with Tourmaline acquisition
Ionis Pharmaceuticals
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
Epigenic
Epigenic secures $60m financing to advance preclinical assets
Senhwa Biosciences CX-5461
Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value
1
2
3
4
5
6
7
